| [1] |
Wang F, Chen G, Zhang Z, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update[J]. Cancer Commun (Lond), 2025, 45(3): 332-379.
|
| [2] |
Wang ZX, Peng J, Liang X, et al. First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial[J]. Med, 2024, 5(9): 1150-1163.
|
| [3] |
Xie M, Yuan K, Zhang Y, et al. Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression[J]. Cancer Cell, 2025, 43(10): 1885-1901.
|
| [4] |
Cai L, Chen A, Tang D. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: multi-pathway combination therapy with PD-1/PD-L1 inhibitors[J]. Immunology, 2024, 173(2): 209-226.
|
| [5] |
Yu L, Guo Q, Gu X, et al. Impact of gut microbiome on radiotherapy and immunotherapy efficacy in microsatellite-stable colorectal cancer: role of propionic acid and B. fragilis[J]. Br J Cancer, 2025, 133(7): 956-969.
|
| [6] |
Zhu L, Tang Z, Jiang W, et al. Cholesterol biosynthesis induced by radiotherapy inhibits cGAS-STING activation and contributes to colorectal cancer treatment resistance[J]. Exp Mol Med, 2025, 57(5): 1089-1105.
|
| [7] |
Liu H, Wang G, Li Z, et al. Exosome-based immunotherapy in hepatocellular carcinoma[J]. Clin Exp Med, 2025, 25(1): 127.
|
| [8] |
Ye J, Li D, Jie Y, et al. Exosome-based nanoparticles and cancer immunotherapy[J]. Biomed Pharmacother, 2024, 179: 117296.
|
| [9] |
Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer[J]. Mol Oncol, 2020, 14(12): 2994-3006.
|
| [10] |
Hsieh RC, Krishnan S, Wu RC, et al. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer[J]. Sci Immunol, 2022, 7(72): eabl9330.
|
| [11] |
Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9): 1276-1282.
|
| [12] |
Tian Y, Liu C, Li Z, et al. Exosomal B7-H4 from irradiated glioblastoma cells contributes to increase FoxP3 expression of differentiating Th1 cells and promotes tumor growth[J]. Redox Biol, 2022, 56: 102454.
|
| [13] |
Krylova SV, Feng D. The machinery of exosomes: biogenesis, release, and uptake[J]. Int J Mol Sci, 2023, 24(2): 1337.
|
| [14] |
Sun B, Zhou Y, Fang Y, et al. Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes[J]. Int J Cancer, 2019, 145(6): 1648-1659.
|
| [15] |
Liu X, Jiang S, Jiang T, et al. Bioenergetic-active exosomes for cartilage regeneration and homeostasis maintenance[J]. Sci Adv, 2024, 10(42): eadp7872.
|
| [16] |
Wang X, Fang Y, Liang W, et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer[J]. Cancer Cell, 2024, 42(10): 1729-1746.
|
| [17] |
Tian S, Wang F, Zhang R, et al. Global pattern of CD8(+) T-cell infiltration and exhaustion in colorectal cancer predicts cancer immunotherapy response[J]. Front Pharmacol, 2021, 12: 715721.
|
| [18] |
Obers A, Poch T, Rodrigues G, et al. Retinoic acid and TGF-beta orchestrate organ-specific programs of tissue residency[J]. Immunity, 2024, 57(11): 2615-2633.
|
| [19] |
Li J, Huang K, Yang B, et al. ATRA upregulates OTUD6B to recruit CD8(+) T cells to suppress colorectal liver metastasis by stabilizing DDX5/STAT3/CXCL11 axis[J]. Cell Death Dis, 2025, 16(1): 521.
|
| [20] |
Lv Y, Chen D, Tian X, et al. Protectin conjugates in tissue regeneration 1 alleviates sepsis-induced acute lung injury by inhibiting ferroptosis[J]. J Transl Med, 2023, 21(1): 293.
|
| [21] |
Derada Troletti C, Enzmann G, Chiurchiù V, et al. Pro-resolving lipid mediator lipoxin A(4) attenuates neuro-inflammation by modulating T cell responses and modifies the spinal cord lipidome[J]. Cell Rep, 2021, 35(9): 109201.
|
| [22] |
Li W, Zhong Q, Deng N, et al. Sphingolipid metabolism-related genes for the diagnosis of metabolic syndrome by integrated bioinformatics analysis and Mendelian randomization identification[J]. Diabetol Metab Syndr, 2025, 17(1): 234.
|
| [23] |
Chen Y, Zhao N, Xu L, et al. Integrative multi-omics analysis reveals the LncRNA 60967.1-PLCD4-ATRA axis as a key regulator of colorectal cancer progression and immune response[J]. Mol Cancer, 2025, 24(1): 164.
|
| [24] |
Soula M, Unlu G, Welch R, et al. Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer[J]. Nature, 2024, 633(8029): 451-458.
|
| [25] |
Zhai S, You Z, Li J, et al. Hybrid-ligand metal-organic frameworks enabling radio-radiodynamic-chemodynamic therapy primes checkpoint blockade immunotherapy in hypoxic tumors[J]. ACS Nano, 2025, 19(33): 30100-30114.
|
| [26] |
Zhai D, An D, Wan C, et al. Radiotherapy: brightness and darkness in the era of immunotherapy[J]. Transl Oncol, 2022, 19: 101366.
|
| [27] |
Yin X, Ding Z, Yu L, et al. Orchestrating intratumoral DC-T cell immunity for enhanced tumor control via radiotherapy-activated TLR7/8 prodrugs in mice[J]. Nat Commun, 2025, 16(1): 6020.
|